Tumorlet and antifibrotic treatment

Czech version

Authors: J. Krynská
Authors‘ workplace: Branislavova 1415/1, 266 01 Beroun
Published in: Reviz. posud. Lék., 23, 2020, č. 3-4, s. 79-82
Category: Original Articles, Review Articles, Case Reports

Overview

Pulmonary fibrotic processes are very inhomogeneous etiologies, destructive changes in lung tissue can occur even in the rare occurrence of hyperplasia of neuroendocrine cells in the lung parenchyma, considered as precancerous. Treatments are ambiguous, often only monitoring is recommended, some studies refer to the concomitant production of profibrotic factors VEGF and TGF-β1 and consider the action of antifibrotics.

Keywords:

diffuse idiopathic neuroendocrine cell hyperplasia – DIPNECH – preneoplasia pulmonary carcinoid tumors – tumorlet – antifibrotic therapy – nintedanib

Sources

1. Ping, He., Xia, Gu., Qinian, Wu., Yunen, Lin., Yingying, Gu., Jianxing, He.: Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis. Journal of Thoracic Disease, December 2012.

2. Wirtschafter E., Walts, A. E., Liu, S. T., Marchevsky, A. M.: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence. National Library od Medicine, Oct. 2015.

3. Myint, Z. W., McCormick, J., Chauhan A., Behrens, E., Lowell, B. A.: Management of Diffuse Idiopathic Pulmonary Neuro-endocrine Cell Hyperplasia: Review and a Single Center Expe-rience. Cureus, September 13, 2019.

Labels

Medical assessment Occupational medicine

Assessment issues in children and adolescents

Principles of correct formulation of conclusions of assessment, use of statements and determination of validity of assessment in assessing disability

Control medical examinations of disability in mental disorders

Invisible poverty among the elderly

Posuzování zdravotního stavu a soběstačnosti/schopnosti samostatného života, závislosti, příspěvek na péči

Article was published in

Medical Revision

2020 Issue 3-4